Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC

Clinical trial NCT06436144 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06436144
Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non Small Cell Lung Cancer EGFR Gene Mutation Non Small Cell Lung Cancer Stage IIIB Non-small Cell Lung Cancer Stage IV

Start date: 2024-06-01
Primary completion: 2029-06-01
Enrollment: 93

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.